All In MedTech

Device Trial Radar · NCT02637947

Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population

A Prospective, Multi-center, Post Market Randomized Controlled Trial Comparing VT Ablation Outcomes Using Remote MAGNETIC Navigation Guided Substrate Mapping and Ablation Versus Manual Approach in a Low LVEF Population

Last checked: Nov 19, 2026Latest source record: Sep 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

182

Actual

Start

Jan 2016

Primary completion

Feb 15, 2022

Study completion Feb 15, 2022

Sponsor

Lead sponsor
StereotaxisPublic (STXS)
Sponsor type
Industry
First posted
Dec 22, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the Niobe™ ES system results in superior outcomes compared to a manual approach in subjects with ischemic scar VT in a low ejection fraction population.

Conditions

  • Tachycardia, Ventricular

Interventions

  • catheter ablation using magnetic navigationDevice

    elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.

  • catheter ablation using manual navigationDevice

    elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. freedom from any VT in the overall cohortTime frame: 12 months

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Florida Hospital

    Orlando, Florida

  • Augusta University

    Augusta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

13 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.